明德生物(002932) - 2025 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2025 reached ¥87,518,775.71, an increase of 22.67% year-over-year[5] - Net profit attributable to shareholders was ¥1,018,186.94, a decrease of 93.55% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was -¥27,707,675.08, a decline of 170.22% year-over-year[5] - Total operating revenue for the current period reached ¥226,808,163.12, a slight increase from ¥225,617,843.38 in the previous period, representing a growth of approximately 0.53%[18] - Operating profit for the current period was reported at -¥17,146,673.26, a significant decline compared to the previous period's profit of ¥82,281,071.77[19] - Net profit for the current period was -¥12,446,113.95, contrasting sharply with a net profit of ¥62,363,772.16 in the previous period[19] - Earnings per share (EPS) for the current period was reported at ¥0.0616, down from ¥0.35 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,101,157,077.56, down 7.46% from the end of the previous year[5] - Total liabilities decreased to ¥373,704,203.24 from ¥574,401,155.88, indicating a reduction of approximately 34.93%[17] - Total equity decreased to ¥5,727,452,874.32 from ¥6,018,677,440.02, reflecting a decline of about 4.83%[17] - Current assets total 4,746,410,239.25 yuan, up from 2,397,670,406.85 yuan at the beginning of the period[16] Cash Flow - Cash flow from operating activities showed a net outflow of -¥88,401,783.99, an increase of 28.28% in outflow compared to the previous year[5] - Cash flow from operating activities was ¥411,843,926.61, compared to ¥600,541,902.81 in the previous period, indicating a decrease of approximately 31.4%[22] - The net cash flow from operating activities was -$123,266,443.84, indicating a decrease in cash generated from operations[23] - Total cash inflow from investment activities was $423,910,028.25, while cash outflow was $568,653,644.73, resulting in a net cash flow of -$144,743,616.48[23] - Cash flow from financing activities resulted in a net outflow of -$250,643,991.12, primarily due to debt repayments and dividend distributions[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,154[12] - The largest shareholder, Chen Lili, holds 27.06% of shares, totaling 62,918,895 shares[12] - The company has a total of 13,034,741 shares in the repurchase account, representing 5.61% of total share capital[13] - The largest ten shareholders do not have any changes in their shareholding due to margin trading[14] - The company has no preferred shareholders or related party transactions reported[14] Expenses - Total operating costs increased to ¥333,278,935.45 from ¥319,893,245.81, marking an increase of about 4.29%[18] - Research and development expenses for the current period were ¥68,672,541.07, down from ¥86,244,236.06, a reduction of about 20.38%[19] - The company reported a significant increase in tax expenses, with current period tax expenses at ¥7,168,116.39 compared to ¥15,710,870.64 in the previous period[19] - Cash paid to employees totaled $183,781,155.10, reflecting the company's payroll expenses[23] - Cash paid for taxes amounted to $8,057,329.16, indicating the company's tax obligations[23] Other Income and Government Subsidies - The company reported a significant increase in other income, reaching ¥16,755,557.44, up 4850% year-over-year, primarily due to interest from overdue receivables[10] - The company received government subsidies totaling ¥2,765,610.95 during the reporting period, down from ¥27,214,812.67 year-to-date[7] Inventory and Receivables - Accounts receivable decreased to 652,510,238.66 yuan from 764,441,414.34 yuan[16] - Inventory increased to 101,353,434.32 yuan from 82,298,479.51 yuan[16] Cash and Cash Equivalents - The company's cash and cash equivalents decreased by 63% to ¥183,864,439.57, mainly due to investments in financial products[10] - The ending balance of cash and cash equivalents was $183,864,439.57, down from $378,206,563.50 at the beginning of the period[24] Audit and Reporting - The company did not undergo an audit for the third-quarter report[24]